Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 7/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1933839 | 0.82 | AURKB (0.61) | AURKBMAPK1NPC1RAB9A | |
| SCHEMBL1933760 | 0.82 | MAPK1 (0.48) | AURKBMAPK1NPC1RAB9AALDH1A1 | |
| SCHEMBL34471939 | 0.81 | AURKB (0.44) | AURKBMAPK1KDRSRC | |
| SCHEMBL1961793 | 0.80 | AURKB (0.51) | AURKBMAPK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1933647 | 0.80 | AURKB (0.61) | AURKBMAPK1NPC1RAB9AALDH1A1 | |
| SCHEMBL1932399 | 0.79 | AURKB (0.45) | AURKBMAPK1KDRFGFR1 | |
| SCHEMBL1933924 | 0.79 | HTT (0.49) | AURKBMAPK1NPC1RAB9AALDH1A1 | |
| SCHEMBL1933597 | 0.78 | RAB9A (0.59) | AURKBMAPK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1933961 | 0.78 | AURKB (0.66) | AURKBMAPK1NPC1RAB9AALDH1A1 | |
| SCHEMBL1933004 | 0.77 | AURKB (1.00) | AURKBMAPK1NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2504336-B1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | ÆTERNA ZENTARIS GMBH (DE) | 2016-03-30 | — | — | EP | disclosed |
| EP-2504336-B1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | ÆTERNA ZENTARIS GMBH (DE) | 2016-03-30 | — | — | EP | disclosed |
| US-8461178-B2 | Naphthyridine derivatives and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2013-06-11 | — | — | US | disclosed |
| US-8461178-B2 | Naphthyridine derivatives and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2013-06-11 | — | — | US | disclosed |
| US-8461178-B2 | Naphthyridine derivatives and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2013-06-11 | — | — | US | disclosed |
| EP-2504336-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | Æterna Zentaris GmbH (DE) | 2012-10-03 | — | — | EP | disclosed |
| US-20110150831-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | AETERNA ZENTARIS GMBH (DE) | 2011-06-23 | — | — | US | disclosed |
| US-20110150831-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | AETERNA ZENTARIS GMBH (DE) | 2011-06-23 | — | — | US | disclosed |
| US-20110150831-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | AETERNA ZENTARIS GMBH (DE) | 2011-06-23 | — | — | US | disclosed |
| EP-2332939-A1 | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors | Æterna Zentaris GmbH (DE) | 2011-06-15 | — | — | EP | disclosed |
| EP-2332939-A1 | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors | Æterna Zentaris GmbH (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2011064250-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | ÆTERNA ZENTARIS GMBH (DE) | 2011-06-03 | — | — | WO | disclosed |
| WO-2011064250-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | ÆTERNA ZENTARIS GMBH (DE) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150831-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K2 | AURKB 389/4885MAPK1 26/4885NPC1 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.